1Spiegelman BM. PPAR - y, Adipogenic regultor and thiazolidinedione receptor.Diabetes 1998,284:751-759.
2Schoonjans K, Martin G, Staels B, et al. Peroxisome proliferator-activated receotors, orphans with ligands and functions.Curr Opin Lipidol 1997,8:159-166.
3Digyb JE, Montague CT, Stewter CP, et al. Thiazolidinediones exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes. Diabetes 1998,47:138-141.
4Nomura, Kinoshita S. Thiaolidine2, 4 - diones as structurally new Antihyperglycemic agents. Bioorg Med Chem Lett 1999,9:533-538.
5Shibuya A, Wantanabe M, Fujita Y, et al. An autopaycase of troglitazone - induced funlminant hypatitis. Diabetes Care 1998,21:2140-2143.
6Elcock FJ, Lyon JJHitchcock J, et al. Toxicity of troglitazone in cultured rat hepatiocytes. Weir GC, Diabetes - 59th Ann Sci Sessions. USA: The American Diabetes Association 1999,A63.
7Saltidel All, Olefsky J. Thiaolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes 1996,45:1661-1667.
8Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus In the 1990s' achivements and funture developments. Drugs 1997,54:355-358.
9Kreider M, Miller E, Petel J. Rosiglitazone is sage and well tolerated as monotherapy or combination therapy in patient with type 2 diabetes Mellitus. Poster accepted for American Diabetes Association Meeting 1999,19-22, San Diego.
